Blennow K - Search Results

1

CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease.

Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E, Brum WS, Rahmouni N, Stevenson J, Servaes S, Therriault J, Becker B, Brinkmalm G, Snellman A, Huber H, Kvartsberg H, Ashton NJ, Zetterberg H, Paquet C, Rosa-Neto P, Blennow K. Lantero-Rodriguez J, et al. Among authors: blennow k. Acta Neuropathol. 2024 Jan 6;147(1):12. doi: 10.1007/s00401-023-02659-w. Acta Neuropathol. 2024. PMID: 38184490 Free PMC article.

2

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blennow K, et al. Acta Neurol Scand. 1990 Apr;81(4):323-6. doi: 10.1111/j.1600-0404.1990.tb01563.x. Acta Neurol Scand. 1990. PMID: 2360400

3

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Blennow K, et al. Mol Chem Neuropathol. 1995 Dec;26(3):231-45. doi: 10.1007/BF02815140. Mol Chem Neuropathol. 1995. PMID: 8748926

4

Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Blennow K, et al. J Neural Transm (Vienna). 1996;103(5):603-18. doi: 10.1007/BF01273157. J Neural Transm (Vienna). 1996. PMID: 8811505

5

The neurochemistry of Alzheimer's disease.

Blennow K, Cowburn RF. Blennow K, et al. Acta Neurol Scand Suppl. 1996;168:77-86. doi: 10.1111/j.1600-0404.1996.tb00378.x. Acta Neurol Scand Suppl. 1996. PMID: 8997425 Review.

6

Neurochemical dissection of synaptic pathology in Alzheimer's disease.

Davidsson P, Blennow K. Davidsson P, et al. Among authors: blennow k. Int Psychogeriatr. 1998 Mar;10(1):11-23. doi: 10.1017/s1041610298005110. Int Psychogeriatr. 1998. PMID: 9629521

7

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Hesse C, et al. Among authors: blennow k. Neurosci Lett. 2001 Jan 19;297(3):187-90. doi: 10.1016/s0304-3940(00)01697-9. Neurosci Lett. 2001. PMID: 11137759 Clinical Trial.

8

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H. Blennow K, et al. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. doi: 10.1385/MN:24:1-3:087. Mol Neurobiol. 2001. PMID: 11831556 Review.

9

The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease.

Zetterberg H, Nexö E, Regland B, Minthon L, Boson R, Palmér M, Rymo L, Blennow K. Zetterberg H, et al. Among authors: blennow k. Clin Chem. 2003 Jul;49(7):1195-8. doi: 10.1373/49.7.1195. Clin Chem. 2003. PMID: 12816923 No abstract available.

10

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H. Blennow K, et al. Lancet Neurol. 2003 Oct;2(10):605-13. doi: 10.1016/s1474-4422(03)00530-1. Lancet Neurol. 2003. PMID: 14505582 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,088 results

Search Page